Clinical Trials
19 trialsNCT06254495 2026-05-08
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
Seagen Inc.
Phase 1 Terminated
NCT06870487 2026-05-08
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
Phase 1 Terminated
NCT06120504 2026-01-26
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
Seagen Inc.
Phase 1 Terminated
NCT05083208 2025-12-02
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
Henan Cancer Hospital
Phase 1 Terminated
NCT04254107 2025-02-10
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Seagen Inc.
Phase 1 Terminated
NCT02978235 2024-09-05
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
Taiho Oncology, Inc.
Phase 1 Terminated
NCT05965505 2024-08-01
Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas
Axter Therapeutics (Beijing) Co., Ltd
Phase 1 Terminated
NCT02663518 2024-05-10
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
Phase 1 Terminated
NCT04548700 2024-03-07
Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Terminated
NCT01769222 2024-01-24
Ipilimumab and Local Radiation for Selected Solid Tumors
Stanford University
Phase 1 Terminated
NCT01644253 2021-05-20
Phase 1b Safety and Efficacy Study of TRU-016
Aptevo Therapeutics
Phase 1 Terminated
NCT01678443 2021-04-02
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Fred Hutchinson Cancer Center
Phase 1 Terminated
NCT03601819 2021-01-22
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT01643603 2020-12-17
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT01609816 2020-03-16
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT00933985 2014-05-01
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00101205 2014-02-24
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00996359 2013-09-17
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
Rutgers, The State University of New Jersey
Phase 1 Terminated
NCT01116154 2010-12-09
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Terminated